Investment
Features
FeesSafety
Academy
More
Pluang+

JPMorgan halts oil price forecasts amid Iran conflict uncertainty and volatile markets

Market News
25 Sep 2026
New York Post
View Source
Bearish
JPMorgan halts oil price forecasts amid Iran conflict uncertainty and volatile markets

JPMorgan's commodities team has stopped providing reliable oil price forecasts due to the ongoing Iran conflict, which has created extreme market volatility and uncertainty. The conflict has disrupted about a quarter of global oil shipments through the Strait of Hormuz and led to fluctuating crude prices, with Brent crude swinging from $72 to $126 and back to around $100 per barrel. The lack of a clear endgame and shifting US-Iran negotiations make it difficult for investors and businesses to predict future oil costs, impacting markets and consumers worldwide. JPMorgan continues to publish estimates but acknowledges the unpredictability of the situation going forward.

JPMorgan's decision to stop forecasting oil prices comes amid volatile market conditions. For readers following the energy sector, here is Pluang's market snapshot as of Sep 25, 2026 17:31 WIB: of 38 priced Energy-sector US stocks tradable on Pluang, 9 rose and 28 fell today. Notable movers include SEDG at USD 32.41 (+1.57%), CCJ at USD 89.32 (+1.36%), and OXY at USD 57.32 (-1.26%) with varying typical hold times and Pluang order activity.

More News

Oklo advances SMR tech and plans first microreactors by 2028 with UBS target at $41.

Oklo advances SMR tech and plans first microreactors by 2028 with UBS target at $41.

Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...

Market News
Bullish
2 hours ago
Barclays rates Ligand Pharmaceuticals 'Overweight' with $345 target on royalty growth.

Barclays rates Ligand Pharmaceuticals 'Overweight' with $345 target on royalty growth.

Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...

Analyst Insights
Bullish
3 hours ago
Three major analysts raise Meta price targets near $920, betting on AI growth beyond ads.

Three major analysts raise Meta price targets near $920, betting on AI growth beyond ads.

JPMorgan, Raymond James, and Bank of America all raised their price targets for Meta Platforms this week, citing the company's new Muse AI as a key growth driver beyond its traditional advertising business. JPMorgan raised its target to $920, Raymond...

Analyst Insights
Bullish
4 hours ago
Forge Resources appoints Kevin Budd as Special Advisor to boost project growth and governance.

Forge Resources appoints Kevin Budd as Special Advisor to boost project growth and governance.

Forge Resources Corp. has appointed Kevin Budd as a Special Advisor, leveraging his 25+ years of global capital markets and corporate development experience. Budd's expertise will support the advancement of Forge's coal project in Colombia and its go...

Company Fundamentals
Bullish
4 hours ago
Four dividend stocks tied to America's freight rail network offer steady returns amid economic cycles.

Four dividend stocks tied to America's freight rail network offer steady returns amid economic cycles.

Four companies linked to America's freight rail network—Union Pacific, CSX, GATX, and Wabtec—offer durable dividend-paying investments due to their entrenched market positions and pricing power. Union Pacific and CSX operate extensive rail networks i...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App